Ranolazine
Modify Date: 2025-08-20 10:51:00
Ranolazine structure
|
Common Name | Ranolazine | ||
|---|---|---|---|---|
| CAS Number | 95635-55-5 | Molecular Weight | 427.536 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 624.1±55.0 °C at 760 mmHg | |
| Molecular Formula | C24H33N3O4 | Melting Point | 119-1200C | |
| MSDS | N/A | Flash Point | 331.2±31.5 °C | |
Use of RanolazineRanolazine is an antianginal medication.Target: Sodium ChannelRanolazine is believed to have its effects via altering the transcellular late sodium current. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level [1]. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia in rats [2]. The effects of ranolazine on the NaV 1.7 and NaV 1.8 sodium channels also make it potentially useful in the treatment of neuropathic pain. Ranolazine produced dose-dependant analgesia on mechanical allodynia induced by CFA injection, but had no effect on thermal hyperalgesia [3, 4]. |
| Name | Ranolazine |
|---|---|
| Synonym | More Synonyms |
| Description | Ranolazine is an antianginal medication.Target: Sodium ChannelRanolazine is believed to have its effects via altering the transcellular late sodium current. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level [1]. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia in rats [2]. The effects of ranolazine on the NaV 1.7 and NaV 1.8 sodium channels also make it potentially useful in the treatment of neuropathic pain. Ranolazine produced dose-dependant analgesia on mechanical allodynia induced by CFA injection, but had no effect on thermal hyperalgesia [3, 4]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 624.1±55.0 °C at 760 mmHg |
| Melting Point | 119-1200C |
| Molecular Formula | C24H33N3O4 |
| Molecular Weight | 427.536 |
| Flash Point | 331.2±31.5 °C |
| Exact Mass | 427.247101 |
| PSA | 74.27000 |
| LogP | 3.47 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.586 |
| InChIKey | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
| SMILES | COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |
| Storage condition | -20°C Freezer |
| Hazard Codes | Xi |
|---|---|
| RIDADR | UN 2811 6.1 / PGIII |
| HS Code | 2933990090 |
CAS#:162712-35-8
CAS#:1131-01-7
CAS#:5294-61-1
CAS#:2210-74-4
CAS#:1427177-23-8
CAS#:90-05-1
CAS#:87-62-7| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| (±)-1-[3-(2-Methoxyphenoxy)-2-hydroxypropyl]-4-[N-(2,6-dimethylphenyl)carbamoylmethyl]piperazine |
| (±)-N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide |
| RAN D |
| Renexa |
| 1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl] |
| N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamid |
| CVT 303 |
| N-(2,6-diméthylphényl)-2-{4-[2-hydroxy-3-(2-méthoxyphénoxy)propyl]pipérazin-1-yl}acétamide |
| (±)-4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2',6'-xylidide |
| 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethy]piperazine |
| N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazinyl}acetamide |
| Ranolazine |
| N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide |
| [14C]-Ranolazine |
| Ran4 |
| MFCD00864690 |
| 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6,dimethylphenyl)-aminocarbonylmethyl]-piperazine |
| Ranexa |
| N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]ethanamide |
| 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]- |
| N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide |